Published online Jun 16, 2021. doi: 10.12998/wjcc.v9.i17.4373
Peer-review started: February 4, 2021
First decision: March 7, 2021
Revised: March 10, 2021
Accepted: April 8, 2021
Article in press: April 8, 2021
Published online: June 16, 2021
Processing time: 110 Days and 20 Hours
Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs, often leading to non-specific lower urinary tract symptoms (LUTS). Approximately 40% of patients with PL have cystitis glandularis (CG). The cause of PL combined with CG is poorly understood, and there is currently no effective treatment. Refractory CG with upper urinary tract obstruction even requires partial or radical bladder resection.
In this case, a patient suffering from PL with CG was treated by transurethral resection of bladder tumour (TUR-BT) and oral administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The LUTS were alleviated, and the cystoscopy results improved significantly. Immunohistochemistry showed up-regulated COX-2 expression in the epithelium of TUR-BT samples, suggesting that COX-2 may participate in the pathophysiological process of PL combined with CG.
We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG.
Core Tip: Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs. The cause of PL with cystitis glandularis (CG) is poorly understood, and there is no effective treatment. This paper reports a patient suffering from PL with CG who was treated by transurethral resection of bladder tumour and oral administration of celecoxib. The lower urinary tract symptoms were alleviated, and the cystoscopy results improved significantly. We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG.